Table 3.

False‐positive report probability analysis for the significant associations between neuroblastoma susceptibility and the rs2094258 C>T and combined risk genotypes of the XPG gene

Genotype	Crude OR (95% CI)	P *	Statistical power†	Prior probability
				0.25	0.1	0.01	0.001	0.0001
XPG rs2094258 C>T
CT versus CC	0.64 (0.46–0.89)	0.008	0.463	0.050	0.136	0.634	0.946	0.994
CT/TT versus CC	0.70 (0.52–0.96)	0.024	0.627	0.103	0.255	0.791	0.974	0.997
CT/TT versus CC
Retroperitoneal	0.52 (0.33–0.83)	0.007	0.110	0.153	0.351	0.856	0.984	0.998
Stage I+II+4s	0.55 (0.37–0.82)	0.003	0.126	0.071	0.186	0.716	0.962	0.996
Risk genotypes
2–3 versus 0–1	1.48 (1.10–2.01)	0.011	0.530	0.057	0.154	0.666	0.953	0.995
>18	1.49 (1.003–2.21)	0.049	0.500	0.206	0.437	0.895	0.989	0.999
Females	1.74 (1.08–2.80)	0.022	0.271	0.195	0.421	0.889	0.988	0.999
Retroperitoneal	2.20 (1.36–3.55)	0.001	0.074	0.046	0.127	0.615	0.942	0.994
Stage I+II+4s	2.10 (1.41–3.13)	0.0003	0.060	0.015	0.043	0.333	0.834	0.981

The significant results were in bold, if the 95% CI excluded 1 or P <0.05. *Chi‐squared test was used to calculate the genotype frequency distributions. ^†Statistical power was calculated using the number of observations in the subgroup and the OR and P‐values in this table.